Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial

Next Previous
Search
Trial Profile

A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary) ; Duloxetine; Escitalopram; Fluoxetine; Paroxetine; Sertraline; Venlafaxine
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational
  • Acronyms Orion
  • Sponsors Otsuka Pharmaceutical Development & Commercialization

    • Most Recent Events

    • 28 Aug 2023 Results of pooled analysis from (NCT01360645, NCT01360632, NCT02196506, and NCT01360866) assessing effect of adjunctive brexpiprazole on metabolic parameters and body weight in adults with MDD and prediabetes published in the Journal of Clinical Psychiatry
    • 01 Nov 2020 Results of pooled analysis from three short-term clinical studies: NCT01360645, NCT01360632, NCT02196506 and long-term studies: NCT01360866 published in the Journal of Clinical Psychopharmacology
    • 15 Sep 2020 Results (n=1547) of post hoc analysis of completion rates in long-term studies (Orion; NCT01360866 and aripiprazole study (NCT00095745)) assessing completion rates and reasons for discontinuation among patients treated with adjunctive brexpiprazole or adjunctive aripiprazole in MDD, presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top